Jagsonpal Pharmaceuticals reported strong Q1FY26 results with revenue up 23% YoY to Rs. 756 Mn, EBITDA at Rs. 157 Mn (20.8% margin), and PAT doubling to Rs. 108 Mn on July 26, 2025.
AI Assistant
Jagsonpal Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.